10066297AMBROSIA: A Multiplexed Plasmo-Photonic Biosensing Platform For Rapid And Intelligent Sepsis Diagnosis At The Point- Of-CareActiveEU-FundedHorizon Europe GuaranteeAMBROSIA aims to provide the foundations for a multi-sensing future-proof Point of Care Unit for sepsis diagnosis offered by a CMOS compatible toolkit and enhanced by on-chip photonic neural network technology to provide an accurate and rapid diagnosis. AMBROSIA will be investing in the established ultra-small-footprint and elevated sensitivity of integrated plasmo-photonic sensors reinforced by the well-known on-chip slow-light effect and micro-transfer printed lasers and photodiodes on Si3N4, as well as the functional processing and classification portfolio of integrated photonic neural network engines, towards painting the landscape of the next-coming disruption in sensor evolution, tailoring them in System-in-Package prototype assemblies, with the sensors being cheap disposable pluggable modules that can rapidly and accurately diagnose sepsis at the bedside in clinical environments. AMBROSIA targets to demonstrate a Point of Care Unit incorporating: i) a switchable sensor area array, with each sensor area facilitating a pluggable, 8-channel label-free plasmo-photonic sensor for sepsis diagnosis with a sensitivity over 130.000nm/RIU and a Limit of Detection below 10-8 RIU for each interferometric sensor, ii) an embedded Si3N4 photonic neural network processing and classifying at the same time the data from at least 7 biomarkers with zero-power providing in the first minutes an accurate and rapid diagnosis for sepsis, iii) Micro transfer printed lasers and photodetectors on chip that will drastically decrease costs of both the sensing and neural network modules, and render the sensor arrays disposable.